Interestingly, it was shown that targeting CAIX enhances the efficacy of bevacizumab, a VEGF targeting antibody, further underlining a possible role for tumor acidity in decreasing the effects of anti-angiogenic drugs [43]. Here, CA9 is linked to neoplasm.